<strong>Antihistam<strong>in</strong>es</strong> for CIUharm: manag<strong>in</strong>g antihistam<strong>in</strong>e impairment <strong>in</strong> patientswith allergic rh<strong>in</strong>itis. J Allergy Cl<strong>in</strong> Immunol.2003;111:S835-S842.17. Howarth PH. The choice <strong>of</strong> an H 1-antihistam<strong>in</strong>e for <strong>the</strong>21st century. Cl<strong>in</strong> Exp Allergy Rev. 2002;2:18-25.18. Bousquet J, Van Cauwenberge P, Khaltaev N, and <strong>the</strong> AriaWorkshop Group, for <strong>the</strong> World Health Organization.Allergic rh<strong>in</strong>itis and its impact on asthma. J Allergy Cl<strong>in</strong>Immunol. 2001;108(suppl 5):S147-S334.19. Babe KS, Seraf<strong>in</strong> WE. Histam<strong>in</strong>e, bradyk<strong>in</strong><strong>in</strong>, and <strong>the</strong>irantagonists. In: Hardman JG, Limbird LE, Mol<strong>in</strong><strong>of</strong>f PB, etal, eds. Goodman and Gilman’s The Pharmacological Basis <strong>of</strong>Therapeutics. Vol 9. New York, NY: McGraw-Hill;1996:587-591.20. Simons FE. <strong>H1</strong>-receptor antagonists. comparative tolerabilityand safety. Drug Saf. 1994;10:350-380.21. Zareba W, Moss AJ, Rosero SZ, et al. Electrocardiographicf<strong>in</strong>d<strong>in</strong>gs <strong>in</strong> patients with diphenhydram<strong>in</strong>e overdose. Am JCardiol. 1997;80:1168-1173.22. Jumbelic MI, Hanzlick R, Cohle S. Alkylam<strong>in</strong>eantihistam<strong>in</strong>e toxicity and review <strong>of</strong> Pediatric ToxicologyRegistry <strong>of</strong> <strong>the</strong> National Association <strong>of</strong> Medical Exam<strong>in</strong>ers.report 4: alkylam<strong>in</strong>es. Am J Forensic Med Pathol.1997;18:65-69.23. Garza MB, Osterhoudt KC, Rutste<strong>in</strong> R. Central antichol<strong>in</strong>ergicsyndrome from orphenadr<strong>in</strong>e <strong>in</strong> a 3 year old.Pediatr Emerg Care. 2000;16:97-98.24. Goetz CM, Lopez G, Dean BS, et al. Accidental childhooddeath from diphenhydram<strong>in</strong>e overdosage. Am J Emerg Med.1990;8:321-322.25. Le Blaye I, Donat<strong>in</strong>i B, Hall M, et al. Acute ketotifen overdosage.a review <strong>of</strong> present cl<strong>in</strong>ical experience. Drug Saf.1992;7:387-392.26. Passalacqua G, Scordamaglia A, Ruffoni S, et al. Sedationfrom <strong>H1</strong> antagonists: evaluation methods and experimentalresults. Allergol Immunopathol (Madr). 1993;21:79-83.27. Cookson J, ed. Use <strong>of</strong> Drugs <strong>in</strong> Psychiatry. Vol 5. London,UK: Gaskell; 2002.28. H<strong>in</strong>dmarch I, Shamsi Z. <strong>Antihistam<strong>in</strong>es</strong>: models to assesssedative properties, assessment <strong>of</strong> sedation, safety and o<strong>the</strong>rside-effects. Cl<strong>in</strong> Exp Allergy. 1999;29(suppl 3):133-142.29. Shamsi Z, H<strong>in</strong>dmarch I. Sedation and antihistam<strong>in</strong>es: areview <strong>of</strong> <strong>in</strong>ter-drug differences us<strong>in</strong>g proportionalimpairment ratios. Hum Psychopharmacol. 2000;15(suppl1):S3-S30.30. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles <strong>of</strong> histam<strong>in</strong>e<strong>in</strong> regulation <strong>of</strong> arousal and cognition: functionalneuroimag<strong>in</strong>g <strong>of</strong> histam<strong>in</strong>e H 1receptors <strong>in</strong> human bra<strong>in</strong>.Life Sci. 2002;72:409-414.31. Paul E, Berth-Jones J, Ortonne J-P, et al. Fex<strong>of</strong>enad<strong>in</strong>ehydrochloride <strong>in</strong> <strong>the</strong> treatment <strong>of</strong> chronic idiopathicurticaria: a placebo-controlled, parallel-group, dose-rang<strong>in</strong>gstudy. J Dermatol Treat. 1998;9:143-149.32. Degonda M, Pichler WJ, Bircher A, et al. Chronic idiopathicurticaria: effectiveness <strong>of</strong> fex<strong>of</strong>enad<strong>in</strong>e. a double-bl<strong>in</strong>d,placebo controlled study with 21 patients [<strong>in</strong> German].Schweiz Rundsch Med Prax. 2002;91:637-643.33. Nelson HS, Reynolds R, Mason J. Fex<strong>of</strong>enad<strong>in</strong>e HCl is safeand effective for treatment <strong>of</strong> chronic idiopathic urticaria.Ann Allergy Asthma Immunol. 2000;84:517-522.34. F<strong>in</strong>n AF Jr, Kaplan AP, Fretwell R, et al. A double-bl<strong>in</strong>d,placebo-controlled trial <strong>of</strong> fex<strong>of</strong>enad<strong>in</strong>e HCl <strong>in</strong> <strong>the</strong> treatment<strong>of</strong> chronic idiopathic urticaria. J Allergy Cl<strong>in</strong> Immunol.1999;104:1071-1078.35. Monroe EW, Bernste<strong>in</strong> DI, Fox RW, et al. Relative efficacyand safety <strong>of</strong> loratad<strong>in</strong>e, hydroxyz<strong>in</strong>e, and placebo <strong>in</strong>chronic idiopathic urticaria. Arzneimittelforschung.1992;42:1119-1121.36. Leynadier F, Duarte-Rissel<strong>in</strong> C, Murrieta M, for <strong>the</strong>URTILOR study group. Comparative <strong>the</strong>rapeutic effect andsafety <strong>of</strong> mizolast<strong>in</strong>e and loratad<strong>in</strong>e <strong>in</strong> chronic idiopathicurticaria. Eur J Dermatol. 2000;10:205-211.37. R<strong>in</strong>g J, He<strong>in</strong> R, Gauger A, et al. Once-daily desloratad<strong>in</strong>eimproves <strong>the</strong> signs and symptoms <strong>of</strong> chronic idiopathicurticaria: a randomized, double-bl<strong>in</strong>d, placebo-controlledstudy. Int J Dermatol. 2001;40:72-76.38. Monroe E, F<strong>in</strong>n A, Patel P, et al, and <strong>the</strong> Desloratad<strong>in</strong>eUritcaria Study Group. Efficacy and safety <strong>of</strong> desloratad<strong>in</strong>e5 mg once daily <strong>in</strong> <strong>the</strong> treatment <strong>of</strong> chronic idiopathicurticaria: a double-bl<strong>in</strong>d, randomized, placebo-controlledtrial. J Am Acad Dermatol. 2003;48:535-541.39. Breneman D, Bronsky EA, Bruce S, et al. Cetiriz<strong>in</strong>e andastemizole <strong>the</strong>rapy for chronic idiopathic urticaria: adouble-bl<strong>in</strong>d, placebo-controlled, comparative trial. J AmAcad Dermatol. 1995;33:192-198.40. Breneman DL. Cetiriz<strong>in</strong>e versus hydroxyz<strong>in</strong>e and placebo<strong>in</strong> chronic idiopathic urticaria. Ann Pharmaco<strong>the</strong>r.1996;30:1075-1079.41. Kawashima M, Harada S, Tango T. <strong>Review</strong> <strong>of</strong> fex<strong>of</strong>enad<strong>in</strong>e<strong>in</strong> <strong>the</strong> treatment <strong>of</strong> chronic idiopathic urticaria. Int JDermatol. 2002;41:701-706.42. Kulthanan K, Gritiyarangsan P, Sitakal<strong>in</strong> C. Multicenterstudy <strong>of</strong> <strong>the</strong> efficacy and safety <strong>of</strong> fex<strong>of</strong>enad<strong>in</strong>e 60 mg twicedaily <strong>in</strong> 108 Thai patients with chronic idiopathic urticaria.J Med Assoc Thai. 2001;84:153-159.43. Thompson AK, F<strong>in</strong>n AF, Schoenwetter WF. Effect <strong>of</strong>60 mg twice-daily fex<strong>of</strong>enad<strong>in</strong>e HCl on quality <strong>of</strong> life,work and classroom productivity, and regular activity <strong>in</strong>patients with chronic idiopathic urticaria. J Am AcadDermatol. 2000;43:24-30.44. Guerra L, V<strong>in</strong>cenzi C, Marchesi E. Loratad<strong>in</strong>e and cetiriz<strong>in</strong>e<strong>in</strong> <strong>the</strong> treatment <strong>of</strong> urticaria. J Eur Acad DermatolVenereol. 1994;3:148-152.45. Boggs PB, Ellis CN, Grossman J. Double-bl<strong>in</strong>d, placebocontrolledstudy <strong>of</strong> terfenad<strong>in</strong>e and hydroxyz<strong>in</strong>e <strong>in</strong> patientswith chronic idiopathic urticaria. Ann Allergy.1989;63:616-620.46. Handa S, Dogra S, Kumar B. Comparative efficacy <strong>of</strong> cetiriz<strong>in</strong>eand fex<strong>of</strong>enad<strong>in</strong>e <strong>in</strong> <strong>the</strong> treatment <strong>of</strong> chronic idiopathicurticaria. J Dermatol Treat. 2004;15:55-57.VOLUME 76, AUGUST 2005 125
<strong>Antihistam<strong>in</strong>es</strong> for CIU47. Gelfand EW, Appajosyula S, Meeves S. Anti-<strong>in</strong>flammatoryactivity <strong>of</strong> H 1-receptor antagonists: review <strong>of</strong> recent experimentalresearch. Curr Med Res Op<strong>in</strong>. 2004;20:73-81.48. Vena GA, Cassano N, Filieri M. Fex<strong>of</strong>enad<strong>in</strong>e <strong>in</strong> chronicidiopathic urticaria: a cl<strong>in</strong>ical and immunohistochemicalevaluation. Int J Immunopathol Pharmacol. 2002;15:217-224.49. Schroeder JT, Schleimer RP, Lichtenste<strong>in</strong> LM, et al. Inhibition<strong>of</strong> cytok<strong>in</strong>e generation and mediator release byhuman basophils treated with desloratad<strong>in</strong>e. Cl<strong>in</strong> ExpAllergy. 2001;31:369-377.50. Sedgwick JB, Busse WW. Inhibitory effects <strong>of</strong> cetiriz<strong>in</strong>e oncytok<strong>in</strong>e-enhanced <strong>in</strong> vitro eos<strong>in</strong>ophil survival. AnnAllergy Asthma Immunol. 1997;78:581-585.51. Ramaekers JG, Vermeeren A. All antihistam<strong>in</strong>es crossblood-bra<strong>in</strong> barrier [letter]. BMJ. 2000;321:572.52. Mann RD, Pearce GL, Shakir S. Sedation with “nonsedat<strong>in</strong>g”antihistam<strong>in</strong>es: four prescription-eventmonitor<strong>in</strong>g studies <strong>in</strong> general practice BMJ.2000;320:1184-1187.53. Verster JC, Volkerts ER. <strong>Antihistam<strong>in</strong>es</strong> and driv<strong>in</strong>gability: evidence from on-<strong>the</strong>-road driv<strong>in</strong>g studies dur<strong>in</strong>gnormal traffic. Ann Allergy Asthma Immunol.2004;92:294-303.54. Salmun LM, Lorber R. 24-hour efficacy <strong>of</strong> once-dailydesloratad<strong>in</strong>e <strong>the</strong>rapy <strong>in</strong> patients with seasonal allergicrh<strong>in</strong>itis. BMC Fam Pract. 2002;3:14.DISCLAIMERThe op<strong>in</strong>ions expressed here<strong>in</strong> are those <strong>of</strong> <strong>the</strong> authors and do not necessarily represent <strong>the</strong> views <strong>of</strong> <strong>the</strong> sponsor or its publisher. Please review complete prescrib<strong>in</strong>g<strong>in</strong>formation <strong>of</strong> specific drugs or comb<strong>in</strong>ation <strong>of</strong> drugs, <strong>in</strong>clud<strong>in</strong>g <strong>in</strong>dications, contra<strong>in</strong>dications, warn<strong>in</strong>gs, and adverse effects before adm<strong>in</strong>ister<strong>in</strong>g pharmacologic<strong>the</strong>rapy to patients.FACULTY DISCLOSUREThe Faculty Disclosure Policy <strong>of</strong> <strong>the</strong> Albert E<strong>in</strong>ste<strong>in</strong> College <strong>of</strong> Medic<strong>in</strong>e requires that faculty participat<strong>in</strong>g <strong>in</strong> a CME activity disclose to <strong>the</strong> audience any relationship witha pharmaceutical or equipment company that might pose a potential, apparent, or real conflict <strong>of</strong> <strong>in</strong>terest with regard to <strong>the</strong>ir contribution to <strong>the</strong> activity. Any discussions<strong>of</strong> unlabeled or <strong>in</strong>vestigational use <strong>of</strong> any commercial product or device not yet approved by <strong>the</strong> US Food and Drug Adm<strong>in</strong>istration must be disclosed.126 CUTIS ®
Change language